FDA Issues CRL to Sobi for NASP in Uncontrolled Gout

FDA Issues CRL to Sobi for NASP: The Agency Rejected the Control System, Not the Drug

No efficacy concern. No safety concern. A launch Sobi valued at SEK 4–6 billion, stopped by a third-party facility. And it was the second of three manufacturing-driven rejections the FDA issued in nine days.

On 26 June 2026, one day before its PDUFA target action date, Sobi disclosed that the FDA had issued a Complete Response Letter for NASP — nanoencapsulated sirolimus plus pegadricase — in adults with uncontrolled gout. The agency asked for additional data on the manufacturing control strategy for the biological component, and for deficiencies at contract manufacturing facilities to be addressed.

It identified no concerns regarding clinical efficacy or safety that impact approvability.

Sobi had initiated a rolling BLA in July 2024. The FDA accepted it on 10 September 2025. Nearly two years of filing activity ended one day short of a decision, on a facility.

Read alone, that is a delay. Read against what happened in the same fortnight, it is something else.

01 — The PatternThree Rejections in Nine Days, None of Them Clinical

Witfire covered three Complete Response Letters in late June 2026. We treated them as separate cases at the time. Placed on one timeline, they are not separate at all.

Three sponsors. Three therapeutic areas. Three completely different molecules — a smoking-cessation alkaloid, a two-component biologic, and a nanoparticle-engineered oral solid. Nine days.

Not one of the three was rejected on its data. All three were rejected on a facility somebody else operates.

02 — The EventWhat the FDA Actually Asked For

The phrase that matters is “manufacturing control strategy of the biological component.” That is not filler.

For a pegylated enzyme like pegadricase, a control strategy covers critical quality attributes, potency and activity assays, the pegylation profile, purity and impurity control, aggregation, stability, process validation, lot-to-lot consistency, analytical method validation, comparability after any manufacturing transfer, release specifications and facility inspection readiness.

Sobi has not specified which of those the agency found insufficient, and it would be wrong to invent one. The category alone carries the regulatory meaning: the FDA was not yet satisfied that the commercial manufacturing system had enough evidence behind it.

There is a second, separable problem. RheumNow reported that the questions concern manufacturing at a third-party facility in China. Sobi’s own statement refers to working with “the contract manufacturing organisations” — plural.

03 — The ProductWhy This Molecule Was Always Going to Be CMC-Heavy

NASP is a sequential two-component infusion given every four weeks.

The clinical logic is elegant. Uricase can break down uric acid, but uricase therapies attract anti-drug antibodies that blunt efficacy and worsen tolerability over repeated dosing. The sirolimus nanoparticle is intended to induce immune tolerance so the enzyme keeps working.

The same elegance is the CMC problem. This is not a tablet, and not even a conventional single-agent biologic. It is a coordinated biologic plus a nanoparticle immunomodulator, administered sequentially, whose entire therapeutic thesis depends on the immune response staying suppressed batch after batch.

The more the mechanism depends on the delivery system, the less forgiving the manufacturing review becomes. A drift in the nanoparticle or the pegylation profile is not a technical loose end in a product like this. It is a threat to the therapy’s identity — the same structural problem we set out in the Unicycive case, where particle engineering made a site change a scientific re-proof rather than a procurement decision.

04 — The DataThe Clinical Package Was Not the Problem

DISSOLVE I and II were double-blind, placebo-controlled Phase 3 trials in adults with chronic refractory gout. Both met the primary endpoint: serum urate below 6 mg/dL for at least 80% of the time during month six.

Both studies were statistically significant. Sobi also reported rapid and sustained urate reduction, tophus improvement, fewer flares over time and improved patient-reported quality of life.

The safety story was not spotless — the DISSOLVE programme reported mild to moderate stomatitis and infusion reactions, with treatment-related serious adverse events including anaphylaxis and gout flares. But the FDA’s own disclosure closes the question: it identified no clinical safety concern affecting approvability.

Chief Medical Officer Lydia Abad-Franch’s framing was that the agency’s feedback provides “a clear and actionable path forward.” On the record available, that is a fair characterisation rather than a spin — which is not something that can be said of every CRL statement.

05 — The DistinctionAn Operational Defeat, Not a Scientific One

This case should be separated from rejections where the agency questioned the evidentiary architecture of the trial itself.

Where RP1 showed that trial architecture can veto an efficacy signal, NASP shows that manufacturing architecture can do the same thing. Different door, same room — and the second is less damaging scientifically while being no less expensive commercially.

Sobi cannot launch. Its gout franchise timing slips. Amgen’s Krystexxa remains the established approved therapy in uncontrolled gout, and every month of delay is a month the incumbent keeps the segment uncontested.

06 — The FranchiseWhy Sobi Is Not a Single-Asset Story

The NASP CRL lands inside a wider gout strategy, and that is the main reason this scores where it does rather than higher.

Sobi completed its acquisition of Arthrosi Therapeutics on 9 February 2026, adding pozdeutinurad (AR882), an investigational once-daily oral URAT1 inhibitor in Phase 3 REDUCE 1 and REDUCE 2 for progressive and tophaceous gout.

On 21 May 2026 — five weeks before the CRL — Sobi reported positive REDUCE 2 topline results. Both doses met the primary endpoint of serum uric acid below 6 mg/dL at month six: 69.2% on 75 mg and 56.6% on 50 mg, against 8.1% placebo.

So the CRL hurts without breaking the thesis. Sobi still has an oral gout asset with positive Phase 3 data addressing a much larger population. What it loses is the complete franchise — NASP was the biologic instrument for the most refractory end of the market, roughly 200,000 US patients with uncontrolled gout out of more than 12 million diagnosed.

The delay is therefore architectural rather than existential. It postpones the two-layer story, not the company.

07 — ScoringWitfire Risk Score

Scored for Sobi on the position created by the CRL. For direct comparison on the same framework: Achieve 3.7, Unicycive 7.5.

The shape is the finding. Evidence Integrity and Capital Position both at 2.5, Regulatory Exposure at 6.5 — this is a company that can afford to wait, holding a drug that has nothing wrong with it, blocked by a building it does not own.

08 — IndiaThe Bar for Complex Biologic Manufacturing

For Indian manufacturers and research organisations, NASP is not a gout lesson. It is a readiness lesson, and it arrives at a useful moment.

Indian pharma talks constantly about moving up the value chain from generics into complex injectables, biosimilars and advanced formulations. This case describes exactly what that move demands, and it is not capacity.

It is biologics analytical characterisation, nanoparticle formulation control, immunogenicity-linked assay strategy, stability under commercial conditions, quality-system readiness that survives an FDA inspection, regulator-grade documentation, comparability packages and inspection preparedness.

There is also a harder point that the three June cases make together. Two of them — Sobi’s China facility, and the single-source Hong Kong manufacturer sitting under obexelimab’s launch — involve Western sponsors dependent on Asian third-party manufacturing that then became a regulatory obstacle. That is the opportunity Indian CDMOs are being offered, and the standard they will be measured against.

Winning that work on cost is possible. Keeping it requires being the vendor whose inspection history never becomes a sponsor’s press release.

09 — PositionInvestor Takeaway

SOBI (Stockholm). This is a timeline event, not a thesis event, and the balance sheet is why. A SEK 4–6 billion projected launch has been deferred by an unknown period, but Sobi funds the remediation from operations, holds a second gout asset with positive Phase 3 data, and faces no dilution question. The variable to track is not whether NASP is approvable — the FDA has effectively said it is — but how much of the remediation clock belongs to a contract manufacturer rather than to Sobi.

The transferable warning. “No clinical safety or efficacy concerns” is the phrase that causes investors to underprice manufacturing CRLs. It sounds like the hard part is done. In all three June cases it was accurate and in none of them did it shorten the delay. A facility problem is not solved with a better Kaplan-Meier curve; it is solved with quality systems, validation, documentation and an inspector’s calendar.

For anyone underwriting a complex biologic. The question to ask before a PDUFA date is not whether the data supports approval. It is whether every site in the chain has been inspected, when, and with what classification — and whether the sponsor can answer that about sites it does not own.

What to watch, in order

1. The FDA meeting outcome. Defines whether the path is data-only, inspection-dependent, or both. Nothing can be timed until this is known.
2. Whether the contract manufacturing deficiencies are isolated or systemic. A single site with a discrete finding is a different problem from a quality system that needs rebuilding, and Sobi controls neither directly.
3. Resubmission classification. Class 1 versus Class 2 determines whether the next review is two months or six, and is the single clearest signal on how the agency views the response.
4. Any requirement for new commercial-scale validation batches. This is the difference between a paperwork cycle and a manufacturing campaign.
5. REDUCE 1 topline for pozdeutinurad. Determines how much weight the oral asset can carry while NASP waits, and therefore how much the delay actually costs.
6. Any change in manufacturing partner. The Achieve case showed that switching early can be the fastest route; the Unicycive case showed what waiting costs. Sobi’s choice here is the most informative decision it will make.

10 — VerdictThe Weakest Layer Sets the Outcome

NASP’s CRL is not a rejection of the molecule. It is a rejection of readiness.

Sobi had a clinically meaningful package. DISSOLVE I and II met their primary endpoints. The FDA said in writing that it had no efficacy or safety concern affecting approvability. On the surface, that makes this one of the better kinds of rejection — and relative to the other two letters that month, it is.

The deeper lesson is harsher, and it does not belong to Sobi alone.

For complex biologics, manufacturing is not downstream of the science. It is the science translated into something a regulator can trust to be reproduced. NASP rests on a difficult promise: use a nanoparticle to blunt anti-drug antibodies so that an enzyme keeps lowering uric acid over years of dosing. That promise is only as good as the control system behind every commercial lot.

The old assumption in biotech was that good clinical data would drag the rest of the application across the line. Late June 2026 should end that assumption. The weakest layer sets the approval outcome, and for an industry that has spent twenty years outsourcing manufacturing, the weakest layer is increasingly the one furthest from the sponsor’s control.

NASP still has a path. The manufacturing system now has to earn it.